uniQure NV QURE
News
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease
UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul
Re/Max, UniQure and Trinseo Fall to 52-Week Lows on Exit From S&P SmallCap 600